Transgene

Transgene is a pioneering biotechnology company established in 1979, headquartered in France. The company focuses on advancing cancer treatment through its innovative immunotherapy solutions. With a slogan promoting "Immunotherapy against cancer," Transgene offers four clinical-stage products backed by its cutting-edge platforms: Invir.IO™ and myvac®.

The company operates within the Biotechnology, Manufacturing, and Pharmaceutical industries, leveraging decades of experience. These strengths position Transgene as a notable player in the biopharmaceutical sector, striving to improve patient outcomes in oncology.

Following its strategic trajectory, the firm recently attracted a €14.00M post-IPO equity investment on 17 July 2023. Although investor details were not disclosed, this capital infusion underscores confidence in Transgene's robust potential. As Transgene continues to advance its clinical pipeline, it presents an attractive opportunity for investors targeting innovation-driven growth in the healthcare sector.